Topics on this week's Pod include:-Lurbinectedin in SCLC-Nivolumab is esophageal cancer-Pembrolizumab for TMB-high cancers-Gemtuzumab ozogamicin for pediatric AML-Venetoclax + HMA for adult (unfit) AML-Gardasil for prevention of SCCHN-Perhaps the biggest non-oncopharm news of the year?